<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02632435</url>
  </required_header>
  <id_info>
    <org_study_id>15-089</org_study_id>
    <nct_id>NCT02632435</nct_id>
  </id_info>
  <brief_title>Randomized Trial Standard of Care Vascular Access Strategies for (Neo)Adjuvant Trastuzumab-based Breast Cancer Treatment.</brief_title>
  <acronym>OTT 15-06</acronym>
  <official_title>A Pragmatic Randomized Trial Standard of Care Vascular Access Strategies for (Neo)Adjuvant Trastuzumab-based Breast Cancer Treatment OTT 15-06 A Study From the REthinking Clinical Trials Program (REaCT-vascular Access Trastuzumab Study).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the REaCT-Vascular Access Trastuzumab study (REaCT-VA), the investigator will use a novel
      method to allow comparisons of established standard of care vascular access strategies using
      the &quot;integrated consent model&quot; as part of a pragmatic clinical trial. The investigator wishes
      to address a non-pharmacologic issue regarding standard of care vascular access devices.
      Peripherally inserted central catheters (PICC lines) versus subcutaneously implanted devices
      (PORTs).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accrual rates</measure>
    <time_frame>one year</time_frame>
    <description>Percentage of patients who receive (neo)adjuvant IV systemic therapy with trastuzumab compared to the number of participants who agree to randomization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient compliance</measure>
    <time_frame>One year</time_frame>
    <description>Percentage of participants who are randomized who accept randomization will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physician engagement</measure>
    <time_frame>One year</time_frame>
    <description>Percentage of medical oncologists who have agreed to participate in the trial compared to the percentage who approached patients regarding the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of events</measure>
    <time_frame>One year</time_frame>
    <description>Rates of documented thrombotic events, need for anticoagulation, line infections, phlebitis, and extravasations during systemic therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Peripherally inserted central catheter</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PICC line will be inserted for the delivery and duration of chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>portacath</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PORT will be inserted for the delivery and duration of chemotherapy and trastuzumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PICC</intervention_name>
    <description>Participants will be randomized to a PICC for vascular access during chemotherapy.</description>
    <arm_group_label>Peripherally inserted central catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PORT</intervention_name>
    <description>Participants will be randomized to a PORT for vascular access during chemotherapy</description>
    <arm_group_label>portacath</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Histologically confirmed primary breast cancer

          -  Planned to start trastuzumab based neo/adjuvant therapy: FEC-DH or AC-DH, or;
             dose-dense AC-TH, or docetaxel/cyclophosphamide/trastuzumab or
             docetaxel/carboplatin/trastuzumab, or weekly paclitaxel with trastuzumab.

          -  ≥19 years of age

          -  Able to provide verbal consent

        Exclusion Criteria

        • Contraindication to central line placement.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Clemons, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ottawa Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Clemons, MD</last_name>
    <phone>613-737-7700</phone>
    <phone_ext>70170</phone_ext>
    <email>mclemons@toh.on.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Ottawa Hospital Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Clemons, MD</last_name>
      <phone>613-737-7700</phone>
      <phone_ext>70170</phone_ext>
      <email>mclemons@toh.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Nancy Page</last_name>
      <phone>613-737-7700</phone>
      <phone_ext>25322</phone_ext>
      <email>napage@toh.on.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2015</study_first_submitted>
  <study_first_submitted_qc>December 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2015</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2 positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

